Allan Rosengren is one of the founder directors and chairman of Bristol Private Equity Club (BPEC) which is one of the primary providers of growth capital in the Bristol area. The seven directors of BPEC all have significant business and PE investing experience. BPEC encompasses over 70 individual private equity investors, with a very broad range of specialisms, focused on investing in growing, ambitious, EIS qualifying businesses in and around Bristol. Between us, we have so far invested over £4million in 15 companies, in some 20 transactions including follow on funding rounds. BPEC are delighted to participate in the inaugural Great West dinner and awards event and look forward to an exceptional evening, enjoyed by all.
Brian is the Entrepreneur in Residence for the Advanced Engineering Business Acceleration Hub at the University of Bath’s SETsquared Innovation Centre. A Mancunian, his early career followed a science degree and began in sales with Duracell. Frustration at the lack of opportunity spawned a move to London, where Brian joined the rapidly-growing PKFA consultancy before moving into marketing with THF. A Gulf War-related redundancy led to his first business - cut short by the chance to run a three- year tourism project on the Lincolnshire Coast. Returning south to join an Amex educational charity led to Brian ‘discovering’ the web and learning to code. Cue the next start-up, a recruitment site eventually acquired by monster.com. Buoyed by this heady success and the completion of his Warwick MBA, another start-up followed, raising £0.5m only for the deal to collapse on the day the market failed in 2001. Suddenly much poorer, Brian returned to the hotel world, joining ICHG in a senior strategy role during a period of seismic change in the industry. After moving to Bath in 2004, he set up BSpark, a niche online marketing business, co-founding the Stay website franchise, while pioneering the regional launch of The Marketing Centre. Now attempting semi-retirement, he can often be found under the bonnet of his beloved 1973 MGB GT or cycling the Two Tunnels path.
Andy is Innovation Manager for the Bristol BioDesign Institute (BBI). He developed and manages the BBI Innovations Programme, which has supported: 5 major platform patents, four new biodesign companies (Zentraxa, CytoSeek, Imophoron and Rosa Biotech) and £4.5M of translational funding. He is building a network of industrial collaborators, manages a range of entrepreneurship training activities including the BBI-SynbiCITE 4-Day More Business Acumen course and is working with local and national government support a new innovation ecosystem in Bristol and the SW. Prior to working at University of Bristol, Andy managed KTN's Synthetic Biology Special Interest Group and was a national contact point for industrial, academic and governmental networking. He has also worked BBSRC, most recently as the UK lead for the Synthetic Biology ERA-NET (ERASynBio).
Andy is a European Patent Attorney and enjoys working on technologies across the chemical, biotech and simple mechanical sectors. He holds a Master’s degree and PhD in chemistry from The University of Bristol, and has carried out post-doctoral research both abroad and in the UK. While in the lab, he worked with a number of multinational pharmaceutical and food and drink companies, and parts of this research resulted in him being a named inventor on a number of patent applications. Andy stepped out of the lab and into the patent profession in 2012. After working at another private practice IP firm for six years, he joined Greaves Brewster LLP in 2018. Andy has helped clients of all sizes, across industry and academia, to understand and navigate the world of patent protection. He strongly values building good relationships with clients and, in particular, getting to know their business well. This allows him to offer targeted and straightforward advice that is in line with each client’s commercial objectives.
Ashley Brewer is the Unit DX Centre Director. Unit DX is a privately funded scientific incubator in the centre of Bristol that opened in May 2017, it is now home to 33 scientific SMEs operating across a broad range of fields, including the life sciences, quantum technologies, and sensor fabrication. Ashley completed his PhD in chemistry at the University of Southampton, conducted post doctoral research at the University of Bristol, and worked at the University of Bath for several years prior to joining the Unit DX team.
Ben Bilsland is RSM’s technology and innovation specialist for Bristol and the South West. RSM is the world’s seventh largest accountancy and business advisory firm with over 43,000 staff across 120 countries. Ben has lived and worked in Bristol for 15 years since graduating from the University of Bristol. He has a deep interest in innovation, technology and companies that are looking to make a real difference in shaping tomorrow’s world. Ben is the accountant and business advisor to a wide range of innovative businesses, from listed corporates to fast-growth start-ups. RSM is really excited to sponsor the Global Good Award. As a business, we are committed to working with entrepreneurial, fast growing businesses. We recognise that running a business is about more than handling profits and losses and we work to help our clients that are looking to change the world into a better place. Innovation and technology are a key driving force for our Bristol office, where we work within the ecosystem. This ranges from free-of-charge accounting and business workshops with PhD students to working with our rapidly expanding client base in this amazing sector.
Allan Rosengren is one of the founder directors and chairman of Bristol Private Equity Club (BPEC) which is one of the primary providers of growth capital in the Bristol area. The seven directors of BPEC all have significant business and PE investing experience. See www.bristolprivateequityclub.com for full details.
David Tew is a GSK Senior Fellow and a member of GSK’s Synthetic Biochemistry group. His role is to seek out new aspects of emerging bioscience, particularly the application of Synthetic Biology, and adapt it for use in new drug manufacturing processes ranging from traditional small molecules through to biopharmaceuticals. In 2018 David was appointed as The Royal Society Entrepreneur in Residence at Bristol University.
Jens Marklof is Professor of Mathematical Physics and Dean of the Faculty of Science at the University of Bristol. His main research interests include dynamical systems and ergodic theory, quantum chaos, and the theory of automorphic forms. After his undergraduate degree from Hamburg and PhD from Ulm, he held postdoctoral positions at Hewlett-Packard, the Newton Institute, IHES and LPTMS Orsay. He moved to Bristol permanently in 1999. Jens delivered a plenary address at the International Congress of Mathematical Physics in Prague 2009, and was an invited section speaker at ICM 2014 in Seoul. Major awards include an EPSRC Advanced Research Fellowship 2001-06, Philip Leverhulme Prize 2004, Marie Curie Excellence Award 2004, Royal Society Wolfson Research Merit Award 2009-14, LMS Whitehead Prize 2010, Leverhulme Trust Research Fellowship 2010-12, and an ERC Advanced Grant 2012-17. In 2015, Jens was elected a Fellow of the Royal Society, the UK’s national academy of sciences.
Jeremy Tavaré is Dean of the Faculty of Life Sciences and Professor of Biochemistry at the University of Bristol and Chair of the MRC’s Non-clinical Training and Careers panel. Closer to home he is Co-Director of the Wellcome Trust-funded GW4 Clinical Academic Training Programme and he holds a number of major devolved portfolio grants from the MRC and Wellcome Trust which he uses strategically to enhance the translation of basic science research into new treatments for disease. Previously, he was the founding Director of the Elizabeth Blackwell Institute for Health Research, which supports innovation through encouraging inter-disciplinary approaches, Deputy Director of the SPHERE Interdisciplinary Research Centre, Deputy Chair of BristolBridge, an antimicrobial resistance research programme, and Deputy Chair of the Scientific Advisory Board of the synthetic biology centre, BrisSynBio. In the 2000s he founded ProXara Biotechnology Limited, a cancer drug discovery company funded largely through investments from the Wellcome Trust and private sources. Outside of academia, he was a semi-professional cricketer for Gloucestershire CCC and played at Lords with the Optimists CC (now Bristol CC) in the 1992 National Club Championship Final beating Kendal, one of the highlights of his life!
Marty Reid is the Centre Director of Future Space at the heart of the University of the West of England’s Enterprise Zone, providing the space, support and community to help science and technology companies reach their potential. With a background spanning engineering and corporate strategy and having worked everywhere from Tokyo to coastal towns in Finland, Marty’s passions lie in bringing innovative people together to solve society’s problems.
Melya Hughes Crameri
Dr. Melya Hughes Crameri is an entrepreneur and partner with Ventac Partners. With 20+ years’ experience in the life sciences industry in the USA and Europe, Melya has served several private companies in corporate strategy and business development. She served as VP Alliances & Intellectual Property of Evolva SA, a synthetic biology company, from Series A to its exit on the SIX Swiss Exchange, and was Founder, President & CEO of Genetic Chemistry Inc. (Evolva’s US subsidiary), securing multi-million dollar discovery contracts and supporting $50M in venture funding. Previously, she served as Head of Licensing and Patents, Novartis Research Foundation (FMI). Melya is a European Patent Attorney and a U.S Patent Agent. She earned her BSc (Hons.) in Biochemistry from Cardiff University and her PhD in Biochemistry from the University of Basel, Switzerland.
Mustafa is presently overseeing the development of the Research and Innovation portfolio for the University of Bristol’s Temple Quarter Enterprise Campus including responsibility for the Institutes of: Digital Futures, Civic Futures and Quantum Innovation. Over the last 8 years Mustafa has been managing the University’s Quantum Technologies programme helping to establish an innovation cluster in the region for Quantum enhanced and inspired businesses, helping to secure large scale government investment in to enterprise and entrepreneurial activities.
Nina is a member of TLT's award winning corporate team with over 12 years' experience advising on seed, venture capital and private equity investments and exits. Nina leads TLT's Fast Growth venture capital team in the South West and her clients are predominantly from young and growing companies, and those that invest in them, be they individuals, venture capital funds and private equity houses or large corporates. She is a member of the firm's Digital team, with particular experience of acting for universities, academics and entrepreneurs on spin out ventures. Nina leads the TLT Women’s Network and was instrumental in its launch this year. The network empowers female members of TLT to achieve their full potential so that there is gender diversity at all levels within the firm and everyone, regardless of their gender, can lead fulfilled, equal and happy working lives. Nina is a regular speaker on the entrepreneurial ecosystem scene at events with leading retail banks, incubators and innovation hubs. Nina also hosts her own events at TLT for start-ups and entrepreneurs to empower them with the legal knowledge to scale up as well as facilitating access to funding.
Phil Bates works at the intersection of cloud product development and research - leading Oracle’s Cloud Innovation Accelerator programme across Europe, the Middle East, and Africa. Phil leads collaborations between Oracle and researchers in academia and industry with computationally and data intensive workloads - helping academics to use state-of-the-art cloud technology and techniques to accelerate the speed of research and discovery. Phil works closely with university professors and researchers at the forefront of their respective fields across a wide range of domains and industries including astrophysics, particle physics. nano-tech design, computational chemistry, life-sciences, health research, environmental and geo-sciences. Phil has over 25 years industry experience delivering high profile software products and cloud services and leading software development teams in the UK, US, Europe and India.
Rick has over 30 years of experience working in high tech industries, predominantly semiconductors and software, including Marconi and STMicroelectronics. Since 2001, Rick has worked in several start-ups. He was a founding executive of SuperH Inc, Cobault Ltd, Spiral Gateway Ltd, and Reveal2me Ltd, covering microprocessor design, commercial software and consumer apps. Rick is currently Entrepreneur-in-Residence at SETsquared Bristol and works with other organisations in Bristol and Bath supporting the high tech cluster. He is also Chair of NuNano Ltd., and Interactive Scientific Ltd., and Managing Director of Parkview Consultants Ltd. Don’t get him talking about cricket.
Rosalind is an experienced university research commercialisation manager and works with academic scientists to get new technologies out of the lab and towards products and services in the market. She has many years of experience in evaluating technologies and markets, protecting and managing intellectual property, business planning, engaging commercial partners, negotiating licences and other contracts and setting up new spin out companies. Rosalind is also a director of a technology-based pharma company and has been a school governor for many years.
Steve set up his growth consultancy, Hare and Tortoise, after 20 years leading Blue Chip and start up clients in media agencies MediaCom and Manning Gottlieb OMD as Client Services Director and then founder of the specialist growth division, Beyond. His inspiration came from a CEO of a business who simply asked what was needed to double demand for the business, how to go about it and how much would it cost. Steve’s approach seeks to unite diverse marketing and business teams around common, consumer-centric commercial goals to harness the opportunities of technology and cultural change in the delivery of next generation products, services and communications. As technology looks to optimise and increasingly automate at pace, this must be done within a bigger strategic vision to look up, to build a differentiating and trusted brand experience, as well as to look down, to performance goals. Steve’s ambition is to help build organisations with effective skills, processes and technology to produce brilliant outcomes that are simple, integrated and tangible.
Stuart previously worked in GE HealthCare’s Medical Diagnostics business, where he led the development of the company's in vitro diagnostics portfolio for their R&D function. He was a founder member of GE's Global Biotechnology Research Council which was tasked with developing innovation through integration of the GE businesses. He also led the Cellular and Molecular Biology team for their Medical Imaging division. Prior to this, Stuart established a research laboratory in New Zealand as a Research Fellow for Diabetes UK. Here he studied diabetes in the native Maori population. He gained his PhD from the University of Nottingham while developing intravascular stent technology for Sulzer-Vascutek Ltd and holds a Bachelor's degree in Pharmacology from Cardiff University.
Tim Gallagher has been both Head of School of Chemistry (2006-12) and from 2013 to summer 2018, Dean of the Faculty of Science at Bristol University. During this time, he has fostered the emergence and growth of spin-out activities across Science and recognised (and supported as far as he was able!) the critical role that UnitDX has played in the creation of Bristol’s “science ecosystem”. During his career, he has worked closely with a number of large and small companies within the pharmaceutical sector, a sector that until very recently was largely lacking in the local region. His expertise is largely within synthetic chemistry and his research is focussed on the discovery of novel agents (often “subtype-selective partial agonists”) for the control of substance addiction. This, in turn, requires a fundamental understanding of the underpinning neurotransmission mechanisms that mediate drug action and, in turn be applied to attenuate addiction. Smoking cessation (nicotine addiction) is a current focus and he collaborates closely with a UK/US industry partner (Achieve Life Sciences) who are progressing a programme of drug discovery in this area.
Tushna is the reviews and careers editor of Physics World, commissioning and writing reviews for a wide range of popular-physics books, plays and films. As part of the careers section, she talks to physicists about the ins and outs of their jobs, across many roles in industry and academia. She also the editor of the annual Physics World Careers guide, and is collaborating with the American Physical Society on a similar publication. She was also the team lead for the Physics World Discovery ebooks programme. Tushna graduated with a BSc in physics from St Xavier’s College, Mumbai, India, before completing a Master’s in science journalism at City University, London. Tushna joined the Physics World team as a news reporter in 2011, and spent the next five years writing about everything from the oriental hornet to antimatter, though she particularly enjoys writing about cosmology and quantum mechanics. Outside work, her favourite pastimes include travelling, photography, science fiction and fantasy in all its forms, and spending a ridiculous amount of time on the Internet.